SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

: Conversations in Pulmonology: March 24, 2018
Activity/Course #:
: 03.24.18CP

: Free
Release/Start Date:
: Mar 24 2018
Expiration Date:
: Mar 24 2018
: Pulmonology
Target Audience:
: Primary Care Providers
: Live Virtual Conferences
Estimated Time To Complete CME Activity:
: 4 hours
: 4.0 AMA PRA Category I Credit(s)
4.0 AANP Contact hour(s) which includes 0.5 pharmacology hour(s)
Hardware/Software Requirements:

There is no registration fee for this CME live virtual conference!

March 24, 2018
Broadcast Live from Ft. Lauderdale, FL
Start Time: 10:00 am EST

Program Summary:

Join Dr. Fernando J. Martinez and stay on track to fulfill your CME requirements from the comfort of your home. Utilizing an interactive, moderator led format, this program will present discussions with national thought leaders to help you hone your skills in the diagnosis and management of patients you are likely encountering in your practice. You will be able to interact with the faculty real-time to get your questions answered.

Learning Objectives:
At the conclusion of this program, participants should be able to:

  1. Discuss the diagnostic approach for IPF incorporating current guidelines and evolving modalities; Discuss emerging data on longer term outcomes for patients treated with nintedanib/pirfenidone; Discuss the approach to diagnosis and treatment of patients with exacerbations of IPF.
  2. Discuss the diagnosis and classification of pulmonary hypertension according to the World Health Organization (WHO) clinical classification system; Outline an approach to rule out and appropriately manage chronic thromboembolic pulmonary hypertension (CTEPH), if present; Recognize the role of upfront, early combination and goal-oriented therapy for pulmonary arterial hypertension (PAH); Describe the management of adverse events with PAH therapies and strategies to improve patient adherence.
  3. Discuss the relationship between alpha-antitrypsin (AAT) protein variants, serum AAT levels, and chronic obstructive pulmonary disease (COPD) risk; Review recommendations for screening in AATD; Review clinical trial data on the use of augmentation therapy for AATD; Discuss strategies to enhance detection and treatment of AATD in clinical practice.
  4. Describe the pathophysiology and the epidemiology of Sarcoidosis; Understand the up-to-date methodology for diagnosis of Sarcoidosis; Review our current understanding of the treatments considered, including steroids, mineralocorticoid receptor agonists and other agents.


10:00-10:10 AM

Welcome Remarks
Fernando Martinez, MD

  The Evolution of IPF Diagnosis and Management:
Incorporating New Data into Practice
Kevin Flaherty, MD, MS and Fernando Martinez, MD
11:10-12:10 PM   Pulmonary Arterial Hypertension and Combination Therapy:
Recognizing the Role, Timing and Strategy
for Advancing Care
Franck Rahaghi, MD, MHS, FCCP and Fernando Martinez, MD


  Diagnosis and Treatment of the Alpha-1 Antitrypsin Deficiency:
A Genetic Subgroup of COPD
Mark L. Brantly, MD and Fernando Martinez, MD
1:40-2:40   Optimizing Diagnosis and Therapy of Pulmonary Sarcoidosis:
Bridging Data and Practice
Franck Rahaghi, MD, MHS, FCCP and Fernando Martinez, MD

Closing Remarks
Fernando Martinez, MD

* Subject to Change

Mark Brantly, MD
Vice Chair of Research, Department of Medicine
Professor of Medicine, Molecular
Genetics and Microbiology
Alpha One Foundation Research Professor
University of Florida College of Medicine
Gainesville, FL

Kevin Flaherty, MD, MS
Professor in Pulmonary and Critical Care Medicine
University of Michigan Health System
Ann Arbor, MI

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY

Planning Committee
Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Joshua F. Kilbridge
President and Creative Director
Kilbridge Associates
San Francisco, CA

Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education
Plantation, FL

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education

Plantation, FL

Gregg Sherman, MD
Course Director
Chief Medical Officer
National Association for Continuing Education
Plantation, FL

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 4 contact hours of continuing education including 0.5 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Commercial Support
This educational activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.; an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; an educational grant from Grifols; and an educational grant from Mallinckrodt Pharmaceuticals.